Choksi Laboratories Ltd
Incorporated in 1982, Choksi Laboratories Ltd provides contract testing and analytical services.[1]
- Market Cap ₹ 97.1 Cr.
- Current Price ₹ 139
- High / Low ₹ 237 / 81.8
- Stock P/E 64.7
- Book Value ₹ 36.7
- Dividend Yield 0.00 %
- ROCE 9.64 %
- ROE 6.10 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 3.80 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 31.5%
- Company has a low return on equity of 5.97% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24.45 | 25.10 | 28.63 | 30.40 | 33.74 | 28.16 | 25.69 | 30.04 | 34.44 | 36.70 | 41.78 | 46.01 | |
| 19.30 | 19.95 | 23.85 | 24.06 | 26.48 | 24.62 | 21.57 | 21.14 | 24.17 | 26.42 | 30.48 | 33.88 | |
| Operating Profit | 5.15 | 5.15 | 4.78 | 6.34 | 7.26 | 3.54 | 4.12 | 8.90 | 10.27 | 10.28 | 11.30 | 12.13 |
| OPM % | 21.06% | 20.52% | 16.70% | 20.86% | 21.52% | 12.57% | 16.04% | 29.63% | 29.82% | 28.01% | 27.05% | 26.36% |
| 0.63 | -0.05 | 0.86 | 0.35 | 0.25 | -2.80 | 0.49 | 0.12 | 2.47 | 0.16 | 0.07 | 0.97 | |
| Interest | 1.57 | 1.23 | 1.47 | 1.59 | 1.54 | 1.89 | 2.82 | 3.23 | 3.52 | 3.06 | 2.72 | 2.82 |
| Depreciation | 2.83 | 2.73 | 2.86 | 3.16 | 3.68 | 4.56 | 4.60 | 5.43 | 5.50 | 5.71 | 6.50 | 7.09 |
| Profit before tax | 1.38 | 1.14 | 1.31 | 1.94 | 2.29 | -5.71 | -2.81 | 0.36 | 3.72 | 1.67 | 2.15 | 3.19 |
| Tax % | 36.23% | 36.84% | 32.06% | 29.90% | 30.13% | -32.05% | -7.12% | 44.44% | 13.71% | 32.93% | 29.30% | 38.56% |
| 0.88 | 0.72 | 0.89 | 1.35 | 1.60 | -3.88 | -2.61 | 0.21 | 3.21 | 1.11 | 1.52 | 1.96 | |
| EPS in Rs | 1.26 | 1.03 | 1.28 | 1.94 | 2.30 | -5.57 | -3.75 | 0.30 | 4.61 | 1.59 | 2.18 | 2.81 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 6% |
| 5 Years: | 12% |
| 3 Years: | 10% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 21% |
| 3 Years: | -3% |
| TTM: | -1% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 28% |
| 5 Years: | 64% |
| 3 Years: | 49% |
| 1 Year: | 29% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 6% |
| 3 Years: | 6% |
| Last Year: | 6% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 | 6.97 |
| Reserves | 12.35 | 13.07 | 14.16 | 15.43 | 17.04 | 13.26 | 10.78 | 10.94 | 14.14 | 15.25 | 16.64 | 18.61 |
| 11.65 | 13.68 | 11.20 | 12.43 | 17.05 | 31.64 | 39.15 | 37.29 | 32.41 | 30.87 | 29.15 | 30.82 | |
| 6.70 | 8.81 | 8.32 | 9.85 | 14.28 | 13.14 | 9.48 | 9.22 | 6.84 | 8.86 | 12.57 | 15.52 | |
| Total Liabilities | 37.67 | 42.53 | 40.65 | 44.68 | 55.34 | 65.01 | 66.38 | 64.42 | 60.36 | 61.95 | 65.33 | 71.92 |
| 19.28 | 17.64 | 22.23 | 28.62 | 34.81 | 33.08 | 50.32 | 46.56 | 44.83 | 43.43 | 47.61 | 51.55 | |
| CWIP | 2.73 | 8.99 | 4.28 | 0.00 | 3.23 | 13.06 | 0.50 | 1.67 | 0.31 | 2.99 | 0.00 | 0.40 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 15.66 | 15.90 | 14.14 | 16.06 | 17.30 | 18.87 | 15.56 | 16.19 | 15.22 | 15.53 | 17.72 | 19.97 | |
| Total Assets | 37.67 | 42.53 | 40.65 | 44.68 | 55.34 | 65.01 | 66.38 | 64.42 | 60.36 | 61.95 | 65.33 | 71.92 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.30 | 0.01 | 6.57 | 6.25 | 6.91 | 2.87 | 5.90 | 7.88 | 8.25 | 11.55 | 11.78 | 7.86 | |
| -0.73 | -0.01 | -1.88 | -4.92 | -9.76 | -13.76 | -7.65 | -2.71 | -0.71 | -6.65 | -7.61 | -7.07 | |
| -1.37 | 0.00 | -4.89 | -0.94 | 2.13 | 11.09 | 1.63 | -5.07 | -7.61 | -4.58 | -4.22 | -1.20 | |
| Net Cash Flow | 0.21 | 0.00 | -0.20 | 0.39 | -0.72 | 0.20 | -0.12 | 0.10 | -0.07 | 0.32 | -0.04 | -0.41 |
| Free Cash Flow | 1.40 | 0.00 | 4.18 | 1.30 | -3.09 | -11.18 | -2.18 | 5.05 | 7.34 | 4.54 | 4.09 | 0.62 |
| CFO/OP | 53% | 0% | 124% | 124% | 137% | 111% | 68% | 75% | 73% | 117% | 122% | 69% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 126.15 | 124.77 | 112.19 | 118.62 | 95.09 | 90.60 | 115.94 | 125.03 | 112.87 | 103.33 | 98.46 | 116.85 |
| Inventory Days | 0.00 | 0.00 | 28.27 | 30.50 | 37.89 | 20.28 | 15.62 | 46.09 | 34.68 | 51.33 | 65.94 | 25.47 |
| Days Payable | 591.13 | 594.31 | 660.70 | 723.24 | 685.97 | 741.06 | 297.29 | 560.33 | 639.34 | 594.19 | ||
| Cash Conversion Cycle | 126.15 | 124.77 | -450.67 | -445.18 | -527.72 | -612.36 | -554.41 | -569.95 | -149.73 | -405.67 | -474.95 | -451.87 |
| Working Capital Days | 29.26 | 3.34 | -23.71 | -18.37 | 28.02 | 21.13 | -49.73 | -23.33 | 11.66 | -49.13 | -71.29 | -35.14 |
| ROCE % | 7.94% | 7.51% | 7.33% | 10.51% | 10.09% | -1.48% | 0.00% | 6.40% | 9.16% | 8.87% | 9.20% | 9.64% |
Insights
In beta| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Block of Plant & Machinery INR Lakhs |
|
||||||||||
| Number of Laboratory Units Number |
|||||||||||
| Median Remuneration Increase % |
|||||||||||
| Number of Permanent Employees Number |
|||||||||||
| Trade Receivables Turnover Ratio times |
|||||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
10h - Submitted Annual Secretarial Compliance Report for FY ended 31 March 2026.
- Result For The Quarter And Year Ended 31.03.2026 10h
-
Board Meeting Outcome for Meeting Of Board Held On 25.05.2026
11h - Board approved FY26 audited results on 25 May 2026; trading window remains closed until 48 hours after declaration.
-
Clarification On Email Dated 19Th May, 2026 By BSE
19 May - Board accepted CFO resignation and approved Mrs. Stela Choksi as CFO on 18 May 2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
18 May - Mrs. Stela Choksi appointed CFO effective 18 May 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Services Offered:[1]
a) Contract Laboratory Services (CLS):
Company provides four different analysis under CLS, viz.
Pharmaceutical Analysis[2]
Food & Beverages Analysis[3]
Water Analysis[4]
Construction Material Analysis[5]
b) Instrument Calibration & Validation Services:[6] Company provides Laboratory and On-Site calibration for test equipment, process equipment, and in many cases end-user equipment, Plant Shutdown Calibration, and consultancy for setting up an in-house calibration laboratory.
c) Environmental Management Services:[7]
Company helps industries develop their Waste Disposal and Effluent Treatment capabilities along with Air Pollution Monitoring, and Waste Water Management
d) Clinical Research Services:[8]
Company has developed a 40-bed clinical research facility for carrying out Bio-Availability and Bio-Equivalence studies
e) Consultancy:[9]
Company provides Training, Auditing, and Consultancy for organizations
f) Assaying & Hallmarking:[10]
Company has set up a gold & silver hallmarking center with EDXRF, Laser assisted marking machine and fire-assay facilities.